Table 3.
Antibiotic susceptibility of Shigella flexneri and Shigella sonnei isolates from 149 males with indigenous shigellosis.
| Drugs | 2010–2014 | 2015–2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| S. flexneri | |||||
| Ampicillin | 0 (0/2) | 21.4 (3/14) | 22.2 (6/27) | 54.1 (20/37) | 72.2 (26/36) |
| Azithromycin | – | 33.3 (2/6) | 79.2 (19/24) | 94.6 (35/37) | 97.1 (33/34) |
| Cefotaxime | 100 (2/2) | 100 (14/14) | 92.6 (25/27) | 97.3 (36/37) | 88.9 (32/36) |
| Ciprofloxacin/levofloxacin | 100 (2/2) | 85.7 (12/14) | 74.1 (20/27) | 35.1 (13/37) | 2.8 (1/36) |
| Trimethoprim-sulfamethoxazole | 50 (1/2) | 78.6 (11/14) | 88.9 (24/27) | 45.9 (17/37) | 52.8 (19/36) |
| S. sonnei | |||||
| Ampicillin | 66.7 (4/6) | 100 (18/18) | 100 (6/6) | 100 (3/3) | – |
| Azithromycin | – | 100 (2/2) | 75 (3/4) | 100 (3/3) | – |
| Cefotaxime | 83.3 (5/6) | 100 (18/18) | 100 (6/6) | 100 (3/3) | – |
| Ciprofloxacin/levofloxacin | 100 (6/6) | 11.1 (2/18) | 0 (0/6) | 0 (0/3) | – |
| Trimethoprim-sulfamethoxazole | 0 (0/6) | 22.2 (4/18) | 66.7 (4/6) | 100 (3/3) | – |
Data are expressed in susceptible percentages (susceptible/total isolates).